StockNews.com Initiates Coverage on Organovo (NASDAQ:ONVO)

StockNews.com started coverage on shares of Organovo (NASDAQ:ONVO) in a report issued on Thursday. The firm set a “sell” rating on the medical research company’s stock.

Organovo Stock Performance

Shares of ONVO opened at $2.41 on Thursday. The firm has a market capitalization of $4.10 million, a P/E ratio of -2.84 and a beta of 0.45. Organovo has a 52 week low of $2.14 and a 52 week high of $21.96. The stock has a 50 day moving average price of $4.92 and a two-hundred day moving average price of $5.10.

Organovo (NASDAQ:ONVO) last announced its quarterly earnings results on Wednesday, February 19th. The medical research company reported ($2.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.52) by $0.24. Organovo had a negative return on equity of 346.26% and a negative net margin of 10,151.64%. The business had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.05 million. On average, equities analysts forecast that Organovo will post -0.77 earnings per share for the current year.

Organovo Company Profile

Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.